One of Lunit's presentations will be on the AI-powered imaging biomarker for breast cancer risk assessment in mammography. Two joint studies in collaboration with the University of Cambridge test the effectiveness of Lunit INSIGHT MMG, a breast cancer detection AI product, to improve the U.K. breast screening workflow. Another joint study in collaboration with the University of Basel focuses on Lunit's CE-marked chest x-ray AI solution, Lunit INSIGHT CXR. Another major study tested the clinical efficacy of utilizing Lunit INSIGHT CXR as part of the prognosis and intervention prediction model for patients with COVID-19.